In the following video, Dr Robert J. Motzer from Memorial Sloan Kettering Cancer Center, in the USA, and a leading kidney cancer specialist in the world, discusses nivolumab (Opdivo) versus everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC). This was first published on the OncLive website here.